Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Appointed director
CC transcript
NPS PHARMACEUTICALS INC (NPSP)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
08/18/2011
BW
NPS Pharmaceuticals Submits Chemistry, Manufacturing and Controls (CMC) Section of New Drug Application for GATTEX®
08/15/2011
BW
NPS Pharmaceuticals Announces Amended Amgen Agreement and Plan to Retire Sensipar-Backed Series B Notes
05/19/2011
BW
NPS Pharmaceuticals to Present at ThinkEquity Healthcare Conference
05/10/2011
BW
GATTEX® (teduglutide) Shown to Reduce Parenteral Support Volume in Patients with Adult Short Bowel Syndrome
05/03/2011
BW
NPS Pharmaceuticals Reports First Quarter 2011 Financial Results
04/28/2011
BW
NPS Pharmaceuticals to Present at Deutsche Bank Securities Health Care Conference
04/27/2011
BW
NPS Pharmaceuticals to Report First Quarter 2011 Financial Results
04/19/2011
BW
NPS Pharmaceuticals Announces Closing of Public Offering of Common Stock
04/13/2011
BW
NPS Pharmaceuticals Prices Upsized Public Offering of Common Stock
04/11/2011
BW
NPS Pharmaceuticals Announces Proposed Public Offering of Common Stock
03/31/2011
BW
NPS Pharmaceuticals to Present at Needham Healthcare Conference
03/28/2011
BW
NPS Pharmaceuticals Partner Submits Application to Market Teduglutide in Europe for Short Bowel Syndrome
03/10/2011
BW
NPS Pharmaceuticals to Present at Barclays Capital Global Healthcare Conference
03/01/2011
BW
NPS Pharmaceuticals Completes Patient Randomization in Phase 3 REPLACE Study of NPSP558 in Hypoparathyroidism
02/28/2011
BW
NPS Pharmaceuticals Launches Educational Website for Short Bowel Syndrome
02/24/2011
BW
NPS Pharmaceuticals to Present at Upcoming Health Care Conferences
02/24/2011
BW
NPS Pharmaceuticals Supports Rare Disease Day
02/15/2011
BW
NPS Pharmaceuticals Reports Financial Results for 2010 and Guidance for 2011
02/11/2011
BW
NPS Pharmaceuticals to Present at Leerink Swann Hot Topics in Therapeutics Roundtable Conference
02/09/2011
BW
NPS Pharmaceuticals to Report 2010 Financial Results
11/18/2010
BW
NPS Pharmaceuticals Appoints Pedro Granadillo to Board of Directors
11/02/2010
BW
NPS Pharmaceuticals Reports Third Quarter 2010 Financial Results and Two Phase 3 Development Programs on Track with Stated Timelines
10/27/2010
BW
NPS Pharmaceuticals to Report Third Quarter 2010 Financial Results
10/15/2010
BW
NPS Pharmaceuticals to Present at NewsMakers in the Biotech Industry Conference
09/21/2010
BW
NPS Pharmaceuticals Announces Closing of $47.5 Million Public Offering of Common Stock and Exercise of Overallotment Option
09/16/2010
BW
NPS Pharmaceuticals Announces Pricing of Public Offering of Common Stock
09/14/2010
BW
NPS Pharmaceuticals to Present at UBS Global Life Sciences Conference
07/29/2010
BW
NPS Pharmaceuticals to Present at Upcoming Conferences
07/28/2010
BW
NPS Pharmaceuticals to Report Second Quarter 2010 Financial Results
07/22/2010
BW
NPS Pharmaceuticals Announces Completion of Patient Randomization in Phase 3 STEPS Study of GATTEX® in Short Bowel Syndrome
06/10/2010
BW
NPS Pharmaceuticals to Present at ThinkEquity Healthcare Conference
05/05/2010
BW
NPS Pharmaceuticals Reports First Quarter 2010 Financial Results and Continued Progress of Two Phase 3 Registration Programs
04/28/2010
BW
NPS Pharmaceuticals to Report First Quarter 2010 Financial Results
04/21/2010
BW
NPS Pharmaceuticals Announces Closing of $56.9 Million Public Offering of Common Stock and Exercise of Overallotment Option
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy